PTD-DBM
Also known as: CXXC5-Dishevelled disrupting peptide, Protein Transduction Domain-Dishevelled Binding Motif
At a glance
PeptiGuide dataset · reviewed Aug 2026
What it is
Preclinical CXXC5–Dishevelled research peptide for hair-follicle biology
Status
Preclinical
Typical dose
1mg
Researched for
Hair loss and hair regrowth research (androgenetic alopecia)
Trial progress
- PrePreclinical
- IPhase I
- IIPhase II
- IIIPhase III
- IVPhase IV
- FDAFDA approved
Preclinical - Promising animal research, limited human data
Use the tools
Stay current
Get updates on PTD-DBM
New studies, regulatory decisions and data corrections - delivered when they land.
In plain language
- Synthetic investigated in hair-follicle biology.
- Reported efficacy evidence is limited to mouse and cell research, predominantly from one laboratory.
- Research commonly paired topical PTD-DBM with valproic acid; human dosing, safety, and efficacy remain unestablished.
How it's thought to work
PTD-DBM combines a protein-transduction domain with a motif that binds Dishevelled. The supplied source reports that this can disrupt CXXC5 association with Dishevelled, increasing Wnt/beta-catenin pathway activity in cell and mouse models. It further reports that valproic acid, described as a GSK-3beta inhibitor, was studied alongside PTD-DBM and produced more activity in the reported model than either component alone. Human validation is not supplied.
What the research shows
Where the research stands
The supplied record attributes the principal work to Lee SH and colleagues in the Choi laboratory at Yonsei University, published in the Journal of Investigative Dermatology in 2017. It describes topical mouse experiments in which PTD-DBM was associated with earlier anagen after shaving and with follicle formation in wounded skin. The source reports solutions of 2 mM PTD-DBM and 500 mM valproic acid, approximately 6 mg/mL and 72 mg/mL respectively, and says this combination performed better than roughly 2 % minoxidil (reported as 100 mM) in that mouse model. It also notes 2024–2025 reviews discussing the compound and its CXXC5-related rationale. No completed peer-reviewed human efficacy study is supplied as of 2026; human , safety, dosing, and real-world effects remain unknown, and the source reports no FDA approval or IND on record.
What it shows
✓ Animal studies
Promising animal research, limited human data
△ Limitations
Animal study doses may not translate directly to humans.
Bottom line: Preclinical - animal (mouse) studies only, no human trials Not FDA Approved
Typical dosing
CommunityCommunity dataset1 mg
or 5 mg vials. A 5 mg vial in about 1 mL of water lands near the ~6 mg/mL used in the mouse study
The source labels this community-reported information anecdotal and unproven; it does not establish a human regimen.
Research dosing
Animal studies onlyAnimal studies only - may not translate to humans
Doses observed in studies
~6 mg/mL PTD-DBM + ~72 mg/mL valproic acid, topical (study reported these as 2 mM and 500 mM)
Preclinical (mouse) study - Lee SH et al., J Invest Dermatol 2017 (Choi lab, Yonsei University)
Animal study doses may not translate directly to humans.
- Duration
- Applied over several weeks in animal studies
- Administration
- Topical (applied to skin) in published research; usually co-applied with valproic acid
Timing & administration
Best time to take
Not established (topical in animal studies)
No established human frequency
Food recommendation
With or without food
Why this timing?
There is no human timing evidence in the supplied record. The reported animal work used skin application and generally included valproic acid.
Possible side effects
Not everyone experiences these. Individual responses vary with dose, duration, and personal factors.
- No human safety data are available in the supplied evidence.
- Possible local skin irritation, with valproic acid identified as a potential contributor.
- Theoretical concern regarding prolonged Wnt/beta-catenin activation and tumor biology.
- Systemic absorption and longer-term safety are unknown.
- Effects in humans remain unproven.
Not everyone experiences side effects, and severity can vary by context, purity, route, and individual health factors.
Frequently asked questions
Sequence
Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Gly-Gly-Gly-Gly-Arg-Lys-Thr-Gly-His-Gln-Ile-Cys-Lys-Phe-Arg-Lys-Cys
One open dataset
Every fact on this page - doses, side effects, references - comes from the same PeptiGuide dataset that powers the Tracker, Compare, and the Lab.
Browse the datasetEducational resource, not medical advice. Talk to your clinician before acting on anything here.
Community discussion
Comments are moderated before they appear. Keep it evidence-focused.